Convertible MRI contrast

Sensing the delivery and release of anti-glioma nano-drugs

Liang Zhang, Zhongwei Zhang, Ralph P. Mason, Jann N. Sarkaria, Dawen Zhao

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As<sup>3+</sup>)-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T<inf>2</inf>-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As<sup>3+</sup>, the active form of ATO, and Mn<sup>2+</sup>, the T<inf>1</inf> contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.

Original languageEnglish (US)
Article number09874
JournalScientific Reports
Volume5
DOIs
StatePublished - May 12 2015

Fingerprint

temozolomide
Manganese
Glioma
Glioblastoma
Pharmaceutical Preparations
Contrast Media
Endosomes
Phosphatidylserines
Lysosomes
Liposomes
Drug Therapy
arsenic trioxide

ASJC Scopus subject areas

  • General

Cite this

Convertible MRI contrast : Sensing the delivery and release of anti-glioma nano-drugs. / Zhang, Liang; Zhang, Zhongwei; Mason, Ralph P.; Sarkaria, Jann N.; Zhao, Dawen.

In: Scientific Reports, Vol. 5, 09874, 12.05.2015.

Research output: Contribution to journalArticle

Zhang, Liang ; Zhang, Zhongwei ; Mason, Ralph P. ; Sarkaria, Jann N. ; Zhao, Dawen. / Convertible MRI contrast : Sensing the delivery and release of anti-glioma nano-drugs. In: Scientific Reports. 2015 ; Vol. 5.
@article{d37c8e6f335041b29e1a7455c279c1e3,
title = "Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs",
abstract = "There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As3+)-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T2-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As3+, the active form of ATO, and Mn2+, the T1 contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.",
author = "Liang Zhang and Zhongwei Zhang and Mason, {Ralph P.} and Sarkaria, {Jann N.} and Dawen Zhao",
year = "2015",
month = "5",
day = "12",
doi = "10.1038/srep09874",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Convertible MRI contrast

T2 - Sensing the delivery and release of anti-glioma nano-drugs

AU - Zhang, Liang

AU - Zhang, Zhongwei

AU - Mason, Ralph P.

AU - Sarkaria, Jann N.

AU - Zhao, Dawen

PY - 2015/5/12

Y1 - 2015/5/12

N2 - There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As3+)-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T2-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As3+, the active form of ATO, and Mn2+, the T1 contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.

AB - There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As3+)-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T2-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As3+, the active form of ATO, and Mn2+, the T1 contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.

UR - http://www.scopus.com/inward/record.url?scp=84929192156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929192156&partnerID=8YFLogxK

U2 - 10.1038/srep09874

DO - 10.1038/srep09874

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 09874

ER -